Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Study sponsor: Immunocore Ltd
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-03Estimated
Enrollment · participants540Estimated
Source updated2026-02-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.